Literature DB >> 16021476

Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children.

Shuichiro Fujinaga1, Kazunari Kaneko, Yoshiyuki Ohtomo, Hitohiko Murakami, Masaru Takada, Shunji Akashi, Mayako Hira, Yuichiro Yamashiro.   

Abstract

Although immunosuppressive regimens of corticosteroids combined with high-dose intravenous cyclophosphamide (IVCY) have been reported to suppress the activity of lupus nephritis, there is controversy regarding its application for children and adolescents, because of its potential toxicity including gonadal dysfunction. On the basis of the recent finding that a low-dose IVCY regimen for induction therapy in adult lupus nephritis effectively achieves renal remission comparable with that achieved with a conventional high-dose IVCY regimen, we treated two children with severe lupus nephritis by low-dose (fixed dose of 500 mg m(-2), cumulative dose 3 g m(-2), approximately one-fourth of the conventional high-dose IVCY regimen) IVCY and oral mizoribine (5 mg kg(-1) day(-1)) and steroids (3 methylprednisolone pulse followed by oral prednisolone). They responded well to this regimen, showing remarkable improvement in both histological and clinical manifestations in a short period of time. From these findings we suggest that the new low-dose IVCY regimen may be as effective as the conventional high-dose IVCY regimen, without significant adverse effect, for induction therapy in children with severe lupus nephritis (class III or IV).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16021476     DOI: 10.1007/s00467-005-1983-9

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  21 in total

1.  Mizoribine for childhood IgA nephropathy.

Authors:  K Kaneko; R Nagaoka; Y Ohtomo; Y Yamashiro
Journal:  Nephron       Date:  1999       Impact factor: 2.847

2.  Sequential therapies for proliferative lupus nephritis.

Authors:  Gabriel Contreras; Victoriano Pardo; Baudouin Leclercq; Oliver Lenz; Elaine Tozman; Patricia O'Nan; David Roth
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

3.  Clinical pharmacokinetic study of mizoribine in renal transplantation patients.

Authors:  K Sonda; K Takahashi; K Tanabe; S Funchinoue; Y Hayasaka; H Kawaguchi; S Teraoka; H Toma; K Ota
Journal:  Transplant Proc       Date:  1996-12       Impact factor: 1.066

Review 4.  Treatment of lupus nephritis in children.

Authors:  P Niaudet
Journal:  Pediatr Nephrol       Date:  2000-02       Impact factor: 3.714

5.  Immunosuppressive effect of bredinin in the management of patients with renal transplantation.

Authors:  R Kusaba; O Otubo; H Sugimoto; I Takahashi; Y Yamada; J Yamauchi; N Akiyama; T Inou
Journal:  Proc Eur Dial Transplant Assoc       Date:  1981

6.  Outcome after transplantation of young patients with systemic lupus erythematosus: a report of the North American pediatric renal transplant cooperative study.

Authors:  S M Bartosh; R N Fine; E K Sullivan
Journal:  Transplantation       Date:  2001-09-15       Impact factor: 4.939

7.  A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome.

Authors:  K Yoshioka; Y Ohashi; T Sakai; H Ito; N Yoshikawa; H Nakamura; T Tanizawa; H Wada; S Maki
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

8.  Mizoribine for the treatment of lupus nephritis in children and adolescents.

Authors:  H Tanaka; K Tsugawa; K Tsuruga; K Suzuki; T Nakahata; E Ito; S Waga
Journal:  Clin Nephrol       Date:  2004-12       Impact factor: 0.975

9.  Mizoribine treatment for childhood IgA nephropathy.

Authors:  Rieko Nagaoka; Kazunari Kaneko; Yoshiyuki Ohtomo; Yuichiro Yamashiro
Journal:  Pediatr Int       Date:  2002-04       Impact factor: 1.524

10.  Efficacy of mizoribine in the treatment of systemic lupus erythematosus in children.

Authors:  Kouichi Yoshidome; Syuji Takei; Hiroyuki Imanaka; Nobuaki Maeno; Toshiya Ohkawa; Yoshifumi Kawano
Journal:  Pediatr Int       Date:  2004-08       Impact factor: 1.524

View more
  4 in total

1.  Evaluation of activity, chronicity and tubulointerstitial indices for childhood lupus nephritis.

Authors:  Michael Zappitelli; Ciarán M Duffy; Chantal Bernard; Indra R Gupta
Journal:  Pediatr Nephrol       Date:  2007-10-24       Impact factor: 3.714

Review 2.  Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy.

Authors:  Hiroshi Tanaka; Kensuke Joh; Tadaatsu Imaizumi
Journal:  Clin Exp Nephrol       Date:  2017-03-03       Impact factor: 2.801

3.  Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen.

Authors:  Shuichiro Fujinaga; Yoshiyuki Ohtomo; Satoshi Hara; Daisuke Umino; Tomonosuke Someya; Toshiaki Shimizu; Kazunari Kaneko
Journal:  Pediatr Nephrol       Date:  2008-04-15       Impact factor: 3.714

4.  The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis.

Authors:  Esra Baskin; Seza Ozen; Nilgun Cakar; Umut S Bayrakci; Erkan Demirkaya; Aysin Bakkaloglu
Journal:  Pediatr Nephrol       Date:  2009-09-01       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.